Status:
COMPLETED
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborating Sponsors:
Technical University of Munich
Conditions:
Coronary Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation
Detailed Description
In patients treated with coronary stents clopidogrel therapy is usually initiated with a 300 to 600 mg loading dose. In the CREDO trial it was shown that a 300 mg loading dose results in a reduction o...
Eligibility Criteria
Inclusion
- Patients with chronic aspirin therapy who are treated with percutaneous coronary intervention at least 2 hours after administration of a 600 mg loading dose of clopidogrel
Exclusion
- Major alterations of blood count (particularly platelet count \< 100x10\^9/l, haemoglobin \< 10 mg/dl
- Recent bleeding diathesis
- Presence of a hematologic or malignant disorder
- Oral anticoagulation with coumarin derivates
- Use of glycoprotein (GP) IIb/IIIa antagonists during the intervention or during the preceding 14 days
- Therapy with clopidogrel within the last 28 days
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00140465
Start Date
October 1 2004
End Date
July 1 2005
Last Update
November 14 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deutsches Herzzentrum Muenchen
Munich, Germany, 80636